White Knight Strategic Wealth Advisors LLC Increases Position in Pfizer Inc. (NYSE:PFE)

White Knight Strategic Wealth Advisors LLC increased its holdings in Pfizer Inc. (NYSE:PFE) by 50.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,154 shares of the biopharmaceutical company’s stock after acquiring an additional 7,772 shares during the period. White Knight Strategic Wealth Advisors LLC’s holdings in Pfizer were worth $614,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of PFE. Tallon Kerry Patrick bought a new position in shares of Pfizer in the fourth quarter valued at approximately $509,000. Ameritas Advisory Services LLC grew its holdings in shares of Pfizer by 3.6% in the fourth quarter. Ameritas Advisory Services LLC now owns 75,983 shares of the biopharmaceutical company’s stock valued at $2,016,000 after acquiring an additional 2,633 shares in the last quarter. Diversify Wealth Management LLC grew its holdings in shares of Pfizer by 13.9% in the fourth quarter. Diversify Wealth Management LLC now owns 10,750 shares of the biopharmaceutical company’s stock valued at $287,000 after acquiring an additional 1,308 shares in the last quarter. Amplius Wealth Advisors LLC lifted its stake in Pfizer by 80.7% in the fourth quarter. Amplius Wealth Advisors LLC now owns 46,823 shares of the biopharmaceutical company’s stock valued at $1,242,000 after purchasing an additional 20,911 shares during the last quarter. Finally, Bonness Enterprises Inc. lifted its stake in Pfizer by 3.4% in the fourth quarter. Bonness Enterprises Inc. now owns 161,508 shares of the biopharmaceutical company’s stock valued at $4,285,000 after purchasing an additional 5,300 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on PFE shares. The Goldman Sachs Group reiterated a “neutral” rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Citigroup reiterated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. UBS Group upped their price objective on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. Finally, Cantor Fitzgerald started coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price objective on the stock. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Price Performance

Pfizer stock opened at $23.51 on Wednesday. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The business has a fifty day moving average price of $23.56 and a 200-day moving average price of $25.27. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a market capitalization of $133.66 billion, a P/E ratio of 16.67, a PEG ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm’s quarterly revenue was down 7.8% on a year-over-year basis. During the same quarter last year, the company earned $0.82 earnings per share. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.32%. The ex-dividend date is Friday, May 9th. Pfizer’s dividend payout ratio is 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.